Sofosbuvir for the treatment of patients with genotype 4 hepatitis C: a review of the clinical efficacy, cost-effectiveness, and guidelines
CADTH
Record ID 32016000175
English
Authors' recommendations:
Sofosbuvir in combination with peginterferon and ribavirin is recommended for treatment of naïve-patients, who are eligible and not eligible to receive interferon, as well as those who are peginterferon/ribavirin non-responders. There was no evidence of comparative clinical efficacy and cost-effectiveness of sofosbuvir for the treatment of HCV genotype 4 identified.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/sites/default/files/pdf/htis/dec-2014/RC0612%20Hep%20C%20Genotype%204%20treatment%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Genotype
- Hepacivirus
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.